Sarepta Faces Investor Skepticism As Duchenne Data Falls Short Of Statistical Significance
1. ESSENCE Phase 3 trial showed no significant efficacy for Amondys 45 and Vyondys 53. 2. FDA meeting planned regarding approval status of the therapies amid trial outcomes. 3. Sarepta reported Q3 revenues of $399.36 million, beating estimates. 4. Analysts express skepticism about future sales of key therapies post trial failure. 5. SRPT stock fell by 33.33% to $16.30 following the trial results.